bioMerieux (0RUG) Share Forecast & Price Target

Compare

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0RUG Analyst Ratings

Moderate Buy

1 Buy

2 Hold

0 Sell

Based on 3 analysts giving stock ratings to

bioMerieux

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0RUG Stock 12 Month Forecast

Average Price Target

€125.33

▲(20.05% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for bioMerieux in the last 3 months. The average price target is €125.33 with a high forecast of €138.00 and a low forecast of €113.00. The average price target represents a 20.05% change from the last price of €104.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"95":"€95","106":"€106","117":"€117","128":"€128","139":"€139"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":138,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€138.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€125.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":113,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€113.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[95,106,117,128,139],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.7,113.72307692307693,115.74615384615385,117.76923076923077,119.7923076923077,121.81538461538462,123.83846153846154,125.86153846153846,127.88461538461539,129.90769230769232,131.93076923076924,133.95384615384614,135.97692307692307,{"y":138,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.7,112.74846153846154,113.79692307692308,114.84538461538462,115.89384615384616,116.9423076923077,117.99076923076923,119.03923076923077,120.08769230769231,121.13615384615385,122.18461538461538,123.23307692307692,124.28153846153846,{"y":125.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.7,111.8,111.9,112,112.10000000000001,112.2,112.3,112.4,112.5,112.6,112.7,112.8,112.9,{"y":113,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":107.96,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.54,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.86,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.89,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.14,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.46,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.21,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.39,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.03,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€138.00

Average Price Target€125.33

Lowest Price Target€113.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Aisyah Noor

Morgan Stanley

€120→€113

Hold

8.24%

Upside

Reiterated

11/05/25

Morgan Stanley Sticks to Its Hold Rating for bioMerieux (0RUG)

Kavya Deshpande

UBS

€132→€138

Buy

32.18%

Upside

Reiterated

10/28/25

UBS Sticks to Their Buy Rating for bioMerieux (0RUG)

Natalia Webster

RBC Capital

€125

Hold

19.73%

Upside

Reiterated

09/22/25

bioMerieux (0RUG) Gets a Hold from RBC Capital

Maja Pataki

Kepler Capital

€140

Buy

34.10%

Upside

Reiterated

09/08/25

Kepler Capital Sticks to Its Buy Rating for bioMerieux (0RUG)

Anchal Verma

J.P. Morgan

€120.5

Hold

15.42%

Upside

Initiated

08/27/25

bioMerieux (0RUG) Initiated with a Hold at J.P. Morgan

Jan Koch

Deutsche Bank

€130→€132

Buy

26.44%

Upside

Reiterated

02/17/25

BioMerieux (BIM:FP) (BMXMF) PT Raised to EUR132 at Deutsche BankDeutsche Bank analyst Jan Koch raised the price target on BioMerieux (BIM:FP) (OTC: BMXMF) to EUR132.00 (from EUR130.00) while maintaining a Buy rating.

Charles Pitman CFA

Barclays

€120→€132

Buy

26.44%

Upside

Reiterated

02/06/25

BioMerieux (BIM:FP) (BMXMF) PT Raised to EUR132 at BarclaysBarclays analyst Gaurav Jain raised the price target on BioMerieux (BIM:FP) (OTC: BMXMF) to EUR132.00 (from EUR120.00) while maintaining a Overweight rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Aisyah Noor

Morgan Stanley

€120→€113

Hold

8.24%

Upside

Reiterated

11/05/25

Morgan Stanley Sticks to Its Hold Rating for bioMerieux (0RUG)

Kavya Deshpande

UBS

€132→€138

Buy

32.18%

Upside

Reiterated

10/28/25

UBS Sticks to Their Buy Rating for bioMerieux (0RUG)

Natalia Webster

RBC Capital

€125

Hold

19.73%

Upside

Reiterated

09/22/25

bioMerieux (0RUG) Gets a Hold from RBC Capital

Maja Pataki

Kepler Capital

€140

Buy

34.10%

Upside

Reiterated

09/08/25

Kepler Capital Sticks to Its Buy Rating for bioMerieux (0RUG)

Anchal Verma

J.P. Morgan

€120.5

Hold

15.42%

Upside

Initiated

08/27/25

bioMerieux (0RUG) Initiated with a Hold at J.P. Morgan

Jan Koch

Deutsche Bank

€130→€132

Buy

26.44%

Upside

Reiterated

02/17/25

Charles Pitman CFA

Barclays

€120→€132

Buy

26.44%

Upside

Reiterated

02/06/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering bioMerieux

1 Month

xxx

Success Rate

16/32 ratings generated profit

Average Return

+0.20%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +0.20% per trade.

3 Months

xxx

Success Rate

18/32 ratings generated profit

Average Return

-0.48%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of -0.48% per trade.

1 Year

Maja PatakiKepler Capital

Success Rate

18/32 ratings generated profit

Average Return

+2.07%

reiterated a buy rating 3 months ago

Copying Maja Pataki's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +2.07% per trade.

2 Years

xxx

Success Rate

17/32 ratings generated profit

Average Return

+5.34%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 53.13% of your transactions generating a profit, with an average return of +5.34% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0RUG Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0RUG has received 4 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. 0RUG average Analyst price target in the past 3 months is 125.33.

Each month's total comprises the sum of three months' worth of ratings.

0RUG Financial Forecast

0RUG Earnings Forecast

Next quarter’s earnings estimate for 0RUG is €2.06 with a range of €2.06 to €2.06. The previous quarter’s EPS was €1.35. 0RUG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 0RUG has Performed in-line its overall industry.

0RUG Sales Forecast

Next quarter’s sales forecast for 0RUG is €1.10B with a range of €1.08B to €1.13B. The previous quarter’s sales results were €2.04B. 0RUG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 0RUG has Performed in-line its overall industry.

0RUG Stock Forecast FAQ

What is GB:0RUG’s average 12-month price target, according to analysts?

Based on analyst ratings, bioMerieux’s 12-month average price target is 125.33.

What is GB:0RUG’s upside potential, based on the analysts’ average price target?

bioMerieux has 20.05% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is bioMerieux a Buy, Sell or Hold?

bioMerieux has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 2 hold ratings and 0 sell ratings.

What is bioMerieux’s share price target?

The average share price target for bioMerieux is 125.33. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €138.00 ,and the lowest forecast is €113.00. The average share price target represents 20.05% Increase from the current price of €104.4.

What do analysts say about bioMerieux?

bioMerieux’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of bioMerieux?

To buy shares of GB:0RUG, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

bioMerieux (0RUG) Share Forecast & Price Target

0RUG Analyst Ratings

0RUG Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering bioMerieux

0RUG Analyst Recommendation Trends

0RUG Financial Forecast

0RUG Earnings Forecast

0RUG Sales Forecast

0RUG Stock Forecast FAQ

Detailed List of Analyst Forecasts